Indoco Remedies Ltd
INDOCO NSE
Indoco Remedies Ltd
HealthcareNSE: INDOCO BSE: 532612 Pharmaceuticals
Key Fundamentals
MicrocapPharmaceuticalsHealthcareMarket Cap
₹2,059 Cr
Volatility
Moderate
P/E Ratio
391.7
EBITDA
₹145 Cr
Return on Equity
-10.59%
Debt to Equity
1.16
Book Value
₹101.76
EPS
₹7.5
52W High
₹332.2
52W Low
₹162.19
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Indoco Remedies Ltd insights
44 extracted metrics + investor summaries across FY15–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Company's working capital requirements have reduced from 40.8 days to 21.3 days
Weaknesses
4- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 8.25% over past five years.
- Company has a low return on equity of -2.45% over last 3 years.
- Earnings include an other income of Rs.98.3 Cr.
Growth Rate
Revenue Growth
10.67% ↘
Net Income Growth
26.54% ↘
Cash Flow Change
102.48% ↗
ROE
38.43% ↗
ROCE
-304.00% ↘
EBITDA Margin (Avg.)
25.20% ↘
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 426 | 482 | 459 | 450 | 431 | 433 | 411 | 390 | 440 | 485 | 445 | 476 | 468 |
| Expenses | 365 | 410 | 397 | 401 | 384 | 392 | 399 | 391 | 422 | 442 | 414 | 426 | 426 |
| Operating Profit | 61 | 71 | 63 | 49 | 48 | 40 | 12 | -1 | 18 | 43 | 32 | 50 | 41 |
| OPM % | 14% | 15% | 14% | 11% | 11% | 9% | 2.9% | -0.2% | 4% | 9% | 7% | 10% | 9% |
| Other Income | 0 | 4 | -6 | 22 | 1 | 2 | 2 | 2 | 2 | 0 | -5 | 4 | 100 |
| Interest | 8 | 8 | 10 | 12 | 14 | 18 | 16 | 18 | 26 | 25 | 26 | 46 | 28 |
| Depreciation | 20 | 21 | 24 | 26 | 28 | 29 | 29 | 29 | 30 | 32 | 32 | 32 | 35 |
| PBT | 34 | 46 | 23 | 33 | 7 | -5 | -31 | -46 | -37 | -14 | -31 | -25 | 78 |
| Tax % | 29% | 24% | 31% | 33% | 74% | 107% | -8% | -9% | -1% | -32% | -6% | -5% | 16% |
| Net Profit | 24 | 35 | 16 | 22 | 2 | -10 | -28 | -41 | -36 | -9 | -29 | -24 | 65 |
| EPS in Rs | 2.65 | 3.81 | 1.77 | 2.46 | 0.28 | -1.04 | -2.86 | -4.38 | -3.88 | -0.86 | -3.23 | -2.34 | 7.04 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 854 | 1,005 | 1,071 | 1,041 | 968 | 1,107 | 1,242 | 1,541 | 1,669 | 1,817 | 1,665 | 1,845 | 1,873 |
| Expenses | 689 | 834 | 914 | 906 | 892 | 983 | 1,017 | 1,213 | 1,381 | 1,572 | 1,565 | 1,703 | 1,708 |
| Operating Profit | 166 | 171 | 157 | 135 | 77 | 123 | 225 | 328 | 288 | 245 | 100 | 142 | 165 |
| OPM % | 19% | 17% | 15% | 13% | 8% | 11% | 18% | 21% | 17% | 13% | 6% | 8% | 9% |
| Other Income | 2 | 1 | 4 | 5 | 6 | 2 | 3 | 2 | 1 | 20 | 6 | 0 | 98 |
| Interest | 11 | 12 | 6 | 24 | 21 | 26 | 22 | 14 | 25 | 38 | 66 | 122 | 124 |
| Depreciation | 47 | 61 | 63 | 68 | 72 | 71 | 73 | 79 | 71 | 92 | 114 | 126 | 131 |
| PBT | 110 | 99 | 91 | 48 | -9 | 29 | 132 | 237 | 193 | 136 | -74 | -106 | 8 |
| Tax % | 24% | 17% | 15% | 15% | -69% | 16% | 30% | 35% | 26% | 29% | 5% | -7% | — |
| Net Profit | 83 | 82 | 77 | 41 | -3 | 24 | 93 | 155 | 142 | 97 | -78 | -99 | 3 |
| EPS in Rs | 8.99 | 8.89 | 8.36 | 4.47 | -0.31 | 2.62 | 10.1 | 16.8 | 15.44 | 10.68 | -7.99 | -10.31 | 0.61 |
| Div. Payout % | 18% | 18% | 19% | 22% | -95% | 11% | 15% | 13% | 15% | 14% | -2% | -2% | — |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 |
| Reserves | 500 | 558 | 633 | 657 | 642 | 661 | 751 | 886 | 1,010 | 1,091 | 1,004 | 921 |
| Borrowings | 97 | 140 | 280 | 282 | 296 | 262 | 267 | 257 | 333 | 672 | 994 | 1,090 |
| Other Liabilities | 230 | 224 | 266 | 281 | 301 | 330 | 279 | 325 | 297 | 363 | 414 | 564 |
| Total Liabilities | 846 | 941 | 1,197 | 1,238 | 1,258 | 1,272 | 1,315 | 1,486 | 1,658 | 2,145 | 2,430 | 2,593 |
| Fixed Assets | 340 | 374 | 440 | 489 | 468 | 590 | 570 | 555 | 678 | 954 | 997 | 1,193 |
| CWIP | 63 | 55 | 91 | 136 | 185 | 51 | 68 | 122 | 114 | 125 | 321 | 90 |
| Investments | 0 | 16 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 9 | 1 | 1 |
| Other Assets | 443 | 496 | 666 | 613 | 605 | 631 | 677 | 809 | 864 | 1,057 | 1,111 | 1,309 |
| Total Assets | 846 | 941 | 1,197 | 1,238 | 1,258 | 1,272 | 1,315 | 1,486 | 1,658 | 2,145 | 2,430 | 2,593 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 109 | 112 | 89 | 123 | 132 | 123 | 82 | 174 | 179 | 157 | 95 | 192 |
| Investing | -88 | -111 | -171 | -135 | -104 | -56 | -67 | -121 | -208 | -433 | -339 | -102 |
| Financing | -20 | -2 | 132 | -39 | -16 | -64 | -30 | -44 | 23 | 280 | 241 | -77 |
| Net Cash Flow | 1 | 0 | 50 | -51 | 12 | 3 | -14 | 8 | -7 | 4 | -3 | 14 |
| Free Cash Flow | 20 | 15 | -100 | -15 | 39 | 64 | 6 | 49 | -27 | -269 | -257 | 91 |
| CFO/OP | 81 | 82 | 72 | 98 | 177 | 103 | 45 | 66 | 84 | 76 | 112 | 139 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 66 | 69 | 74 | 73 | 74 | 69 | 69 | 70 | 77 | 82 | 77 | 97 |
| Inventory Days | 181 | 174 | 189 | 203 | 209 | 230 | 245 | 248 | 228 | 230 | 307 | 273 |
| Days Payable | 146 | 137 | 166 | 157 | 195 | 183 | 117 | 107 | 86 | 100 | 152 | 208 |
| Cash Conversion Cycle | 102 | 105 | 97 | 119 | 88 | 116 | 197 | 212 | 219 | 212 | 232 | 162 |
| Working Capital Days | 46 | 48 | 41 | 38 | 21 | 22 | 59 | 78 | 82 | 62 | 39 | 21 |
| ROCE % | 21% | 17% | 12% | 7% | 1% | 6% | 16% | 23% | 17% | 10% | 0% | 1% |
Documents
1
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
16h - Transcript of Earnings Conference Call on Audited Standalone and Consolidated Financial Results for the Quarter and Year ended 31-03-2026 16h - Transcript of Earnings Conference Call on Audited Standalone and Consolidated Financial Results for the Quarter and Year ended 31-03-2026
2
Announcement under Regulation 30 (LODR)-Newspaper Publication
8 May - Publication of Audited Standalone & Consolidated Financial Results for the Quarter and Year ended 31-03-2026 8 May - Publication of Audited Standalone & Consolidated Financial Results for the Quarter and Year ended 31-03-2026
3
Announcement under Regulation 30 (LODR)-Press Release / Media Release
30 Apr - Indoco Remedies announces strategic transfer of its opthalmic division to Sunways India 30 Apr - Indoco Remedies announces strategic transfer of its opthalmic division to Sunways India
4
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
30 Apr - Indoco Remedies approved and executed ATB to sell ophthalmic division to Sunways for Rs.110 crore. 30 Apr - Indoco Remedies approved and executed ATB to sell ophthalmic division to Sunways for Rs.110 crore.
5
Board Meeting Outcome for Outcome Of Board Meeting Held On 07Th May, 2026
7 May - Board approved audited Q4/FY26 standalone and consolidated results; recommended Rs.0.20 dividend per share. 7 May - Board approved audited Q4/FY26 standalone and consolidated results; recommended Rs.0.20 dividend per share.
3
Notice Of 79Th Annual General Meeting And Annual Report For The Financial Year 2025-2026 21 Aug 2026
Intimation
4
Notice Of 79Th Annual General Meeting And Annual Report For The Financial Year 2025-2026 21 Aug 2026
Intimation
Frequently Asked Questions about Indoco Remedies Ltd
What does Indoco Remedies Ltd do?
Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredi...
Where is Indoco Remedies Ltd (INDOCO) listed?
Indoco Remedies Ltd is listed on the Indian stock exchanges. It is listed on NSE: INDOCO and BSE: 532612. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Indoco Remedies Ltd belong to?
Indoco Remedies Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Indoco Remedies Ltd?
Indoco Remedies Ltd has a market capitalisation of approximately ₹2059.48 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of Indoco Remedies Ltd?
The Price-to-Earnings (PE) ratio of Indoco Remedies Ltd is 391.70. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Indoco Remedies Ltd?
Over the past 52 weeks, Indoco Remedies Ltd has traded between a low of ₹162.19 and a high of ₹332.2. This range helps investors understand the stock's price volatility and recent trading levels.
Does Indoco Remedies Ltd pay dividends?
Yes, Indoco Remedies Ltd has a dividend yield of 0.09%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Indoco Remedies Ltd?
Indoco Remedies Ltd has a Return on Equity (ROE) of -10.59%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Indoco Remedies Ltd on Tapetide?
On Tapetide, you can view Indoco Remedies Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).[1]
Website indoco.com
CEO Mr. Suresh Govind Kare
Employees 6,000
Listed 2005-01-14
Face Value ₹ 2
Issued Size 9,22,47,905